Literature DB >> 10636134

The Oregon brain aging study: neuropathology accompanying healthy aging in the oldest old.

M S Green1, J A Kaye, M J Ball.   

Abstract

OBJECTIVE: To describe the relationship between neuropathologic aging and longitudinal measures of cognitive function in healthy oldest old individuals.
METHODS: Nondemented individuals without cardiovascular or other age-associated diseases of age > or =85 years were followed until death. Regional postmortem measures of senile plaque (SP) and neurofibrillary tangle (NFT) severity were examined in relationship to clinical status, cognitive measures, and rate of cognitive change.
RESULTS: Among 19 healthy individuals, 10 became demented or had incipient dementia develop. Clinical status and rate of change in cognitive scores correlated with increasing brain lesion burden, particularly in neocortical regions. Compared to demented individuals, nondemented individuals had few or no neocortical NFT (p = 0.009) or SP (p = 0.001). There was a strong correlation between rate of cognitive change on Mini-Mental State Examination (MMSE) and neocortical NFT (r = 0.859, p = 0.001). The few NFT and SP in nondemented patients had a predilection for limbic areas.
CONCLUSIONS: These results support a continuum in which AD is infrequent in the healthy, cognitively stable, oldest old. The minimal abnormalities in cognitively stable individuals are consistent with the notion that preclinical pathologic AD precedes obvious cognitive impairment. Longitudinal cognitive testing shows an increased burden of neuropathologic changes in those who have cognitive decline but are not functionally impaired and do not meet criteria for the diagnosis of dementia. The strong relationship between cumulative pathologic changes and rate of cognitive decline suggests that these lesions may have clinical consequences at any age and are not likely to be benign senescent changes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10636134     DOI: 10.1212/wnl.54.1.105

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  55 in total

1.  Neurodegenerative basis of age-related cognitive decline.

Authors:  R S Wilson; S E Leurgans; P A Boyle; J A Schneider; D A Bennett
Journal:  Neurology       Date:  2010-09-15       Impact factor: 9.910

2.  Age and diagnostic performance of Alzheimer disease CSF biomarkers.

Authors:  N Mattsson; E Rosén; O Hansson; N Andreasen; L Parnetti; M Jonsson; S-K Herukka; W M van der Flier; M A Blankenstein; M Ewers; K Rich; E Kaiser; M M Verbeek; M Olde Rikkert; M Tsolaki; E Mulugeta; D Aarsland; P J Visser; J Schröder; J Marcusson; M de Leon; H Hampel; P Scheltens; A Wallin; M Eriksdotter-Jönhagen; L Minthon; B Winblad; K Blennow; H Zetterberg
Journal:  Neurology       Date:  2012-02-01       Impact factor: 9.910

Review 3.  Ageing and the brain.

Authors:  R Peters
Journal:  Postgrad Med J       Date:  2006-02       Impact factor: 2.401

4.  Expanding ventricles may detect preclinical Alzheimer disease.

Authors:  Michael W Weiner
Journal:  Neurology       Date:  2008-03-11       Impact factor: 9.910

Review 5.  Asymptomatic Alzheimer's disease: a prodrome or a state of resilience?

Authors:  I Driscoll; J Troncoso
Journal:  Curr Alzheimer Res       Date:  2011-06       Impact factor: 3.498

6.  Cognitive decline in the elderly: an analysis of population heterogeneity.

Authors:  Kathleen M Hayden; Bruce R Reed; Jennifer J Manly; Douglas Tommet; Robert H Pietrzak; Gordon J Chelune; Frances M Yang; Andrew J Revell; David A Bennett; Richard N Jones
Journal:  Age Ageing       Date:  2011-09-02       Impact factor: 10.668

7.  Clinico-Neuropathological Findings in the Oldest Old from the Georgia Centenarian Study.

Authors:  Jirayu Tanprasertsuk; Elizabeth J Johnson; Mary Ann Johnson; Leonard W Poon; Peter T Nelson; Adam Davey; Peter Martin; Aron K Barbey; Kathryn Barger; Xiang-Dong Wang; Tammy M Scott
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

8.  Risk of incident clinical diagnosis of Alzheimer's disease-type dementia attributable to pathology-confirmed vascular disease.

Authors:  Hiroko H Dodge; Jian Zhu; Randy Woltjer; Peter T Nelson; David A Bennett; Nigel J Cairns; David W Fardo; Jeffrey A Kaye; Deniz-Erten Lyons; Nora Mattek; Julie A Schneider; Lisa C Silbert; Chengjie Xiong; Lei Yu; Frederick A Schmitt; Richard J Kryscio; Erin L Abner
Journal:  Alzheimers Dement       Date:  2016-12-23       Impact factor: 21.566

9.  Factors associated with resistance to dementia despite high Alzheimer disease pathology.

Authors:  D Erten-Lyons; R L Woltjer; H Dodge; R Nixon; R Vorobik; J F Calvert; M Leahy; T Montine; J Kaye
Journal:  Neurology       Date:  2009-01-27       Impact factor: 9.910

10.  Brain atrophy in healthy aging is related to CSF levels of Aβ1-42.

Authors:  Anders M Fjell; Kristine B Walhovd; Christine Fennema-Notestine; Linda K McEvoy; Donald J Hagler; Dominic Holland; Kaj Blennow; James B Brewer; Anders M Dale
Journal:  Cereb Cortex       Date:  2010-01-04       Impact factor: 5.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.